• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Financial Toxicity and Willingness-to-Pay for Cancer Treatment Among People With Multiple Myeloma

by | Jun 17, 2024 | Publications

JCO Oncol Pract. 2024 Jun 17:OP2400016. doi: 10.1200/OP.24.00016. Online ahead of print. ABSTRACT PURPOSE: This study used willingness-to-pay (WTP) exercises to explore the relationships between race, financial toxicity, and treatment decision making among people with...

Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma

by | Jun 17, 2024 | Publications

Res Sq [Preprint]. 2024 Jun 5:rs.3.rs-4406606. doi: 10.21203/rs.3.rs-4406606/v1. ABSTRACT Lenalidomide maintenance is associated with a significantly improved progression-free in patients with newly diagnosed multiple myeloma. Maintenance with lenalidomide is...

Denosumab-Induced Maxillary Osteonecrosis: A Case Study on Long-Term Complications in Multiple Myeloma Treatment

by | Jun 17, 2024 | Publications

Ear Nose Throat J. 2024 Jun 16:1455613241263181. doi: 10.1177/01455613241263181. Online ahead of print. ABSTRACT Background: Targeted therapies like denosumab have revolutionized multiple myeloma (MM) treatment, improved patient outcomes while introducing long-term...

Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?

by | Jun 17, 2024 | Publications

Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024044. doi: 10.4084/MJHID.2024.044. eCollection 2024. ABSTRACT The study of monoclonal serum proteins has led to the generation of two major theories: one proposing that individuals who had monoclonal proteins without...

Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study

by | Jun 17, 2024 | Publications

Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024041. doi: 10.4084/MJHID.2024.041. eCollection 2024. NO ABSTRACT PMID:38882459 | PMC:PMC11178051 | DOI:10.4084/MJHID.2024.041

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

by | Jun 16, 2024 | Publications

J Clin Oncol. 2024 Jun 16:JCO2401008. doi: 10.1200/JCO.24.01008. Online ahead of print. ABSTRACT PURPOSE: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3...
« Older Entries
Next Entries »

Recent Content

  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
  • Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
  • Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
  • (no title)
  • FDA OK’s belantamab mafodotin-blmf for multiple myeloma
  • Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT